Mike Havrilla
Long-term horizon

Ventrus Poised For Run-Up Ahead Of Phase III Results

Ventrus Biosciences (VTUS) develops new treatments for gastrointestinal (NYSE:GI) disorders with a lead product candidate (Diltiazem Topical Cream or VEN 307) that is currently being evaluated in the second of two planned pivotal Phase III clinical trial.


VTUS expects to report results from the second of two pivotal Phase III clinical trials (ClinicalTrials.gov ID NCT01690221) for the relief of pain associated with anal fissures during Q4 2013 to support a planned 505(b)(2) NDA filing for a novel topical formulation of an approved calcium channel blocker drug (diltiazem). Last May, EU partner S.L.A. Pharma reported positive results in the first Phase III clinical trial for VEN-307.

ClinicalTrials.gov IDs NCT01816529, NCT01821274 and NCT01816191 are...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details